Properties and potential of ertapenem

Area of Science:

• Pharmacology and Microbiology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Ertapenem is a carbapenem antibiotic with broad-spectrum activity.
• Its efficacy is maintained against strains with AmpC and extended-spectrum beta-lactamases.
• Resistance can emerge with combined enzyme activity and impermeability, or via carbapenemases, though these are currently rare.

Purpose of the Study:

• To review the clinical efficacy and pharmacokinetic profile of ertapenem.
• To assess ertapenem's activity against common bacterial pathogens and resistance mechanisms.
• To discuss potential expanded uses and public health implications of ertapenem's wider application.

Main Methods:

• Review of existing clinical trial data comparing ertapenem to piperacillin/tazobactam and ceftriaxone.
• Analysis of ertapenem's in vitro activity against various bacterial species, including resistant strains.
• Pharmacokinetic assessment based on plasma half-life and excretion patterns.

Main Results:

• Ertapenem demonstrated equivalent efficacy to piperacillin/tazobactam or ceftriaxone in intra-abdominal infections, community-acquired pneumonia, acute pelvic infections, skin infections, and complicated urinary tract infections.
• Its activity is retained against most strains with AmpC and extended-spectrum beta-lactamases.
• Carbapenemase-mediated resistance, while a future concern, is currently rare and often requires co-existing impermeability for significant impact.

Conclusions:

• Ertapenem is a valuable therapeutic option for several common infections, supported by robust clinical trial data.
• The current rarity of carbapenemases and ertapenem's spectrum of activity provide some reassurance regarding resistance.
• Careful monitoring of resistance ecology is crucial if ertapenem usage is to be significantly widened.